Abstract: The production of vectors composed of portions of retrovirus, particularly of Moloney sarcoma virus DNA including the "LTR" sequence which can activate genes and additional viral sequences which can "rescue" these genes into a replicating virus particle.
Type:
Grant
Filed:
July 1, 1981
Date of Patent:
September 20, 1983
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
George F. Vande Woude, William L. McClements, Marianne K. Oskarsson, Donald G. Blair
Abstract: A process for producing a high quality protein fish meal from whole fish, including trash fish, either on board ship or on shore, by using an appropriate proteolytic enzyme which liquefies the fish in a digester equipped with high speed blenders, liquefying the fish by heating in the digester, pasteurizing the liquid fish so that the liquid can be stored under refrigeration for several weeks without spoilage, screening the bones out, and centrifuging part of the oil, if necessary, then drying it.
Type:
Grant
Filed:
September 9, 1980
Date of Patent:
September 20, 1983
Assignee:
Marvin Dudley
Inventors:
George A. Jeffreys, James F. Tobey, Jr., Jean L. Price
Abstract: A bisulfite addition product of 5-azacytidine and method wherein bisulfite is added to the azacytidine molecule at the 5-6 protonated imine bond. It is significant and advantageous to maintain the compound in this pro-drug form. At a pH above 6 and including higher physiological pH in animals, the bisulfite form reverts to the parent compound, rendering it readily available for utilization in the body. This product is produced as the bisulfite addition product at preferably a pH of 2.5.
Type:
Grant
Filed:
December 18, 1981
Date of Patent:
September 20, 1983
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: The present invention is directed towards the examination of formulations and evaluations of ethiodized oil emulsions. It is also concerned with formulations of ethiodized oil emulsified with lecithin which show about 30-35% of oil particles in the range 2-3 microns. A dosage utilized for animals, such as rabbits and monkeys for this ethiodized emulsion is 0.1-0.5 ml/kg utilizing computerized tomography, with a preferred dosage of 0.2 ml/kg for computerized tomography, and a dosage of 2 ml/kg for conventional X-rays.
Type:
Grant
Filed:
January 8, 1980
Date of Patent:
September 13, 1983
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Michael Vermess, Dulal C. Chatterji, George J. Grimes, Jr., Joseph F. Gallelli
Abstract: A new reagent effective in inhibiting cholesterol synthesis 75% in human fibroblasts derived from patients suffering from the disease familial hypercholestrolemia is Man6P-low density lipoprotein and is effective in tissue culture test systems at 100 .mu.g/ml after a ten-hour exposure. The broad purpose of this invention is to modify the receptor specificity of a protein so that it will enter cells which were previously impermeable and exert new effects or reverse a pathological condition. That is, the compound of this invention is a useful reagent in the selective cytotoxic treatment of hypercholesterolemia.
Type:
Grant
Filed:
January 21, 1982
Date of Patent:
August 9, 1983
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
David M. Neville, Jr., Richard J. Youle, Gary J. Murray
Abstract: This invention pertains to an improved energy-saving fuel additive for jet engines, gasoline and diesel engines, including additions to domestic heating and light industrial oils (#2 and #3) and residual or bunker fuel (#4, #5, and #6), which comprises as active ingredients a catalytic mixture of a major proportion of picric acid and a minor proportion of cupric sulfate.______________________________________ Cupric sulfate .01-.03% Picric acid 1-2% Methanol 35-50% Isopropyl alcohol 15-5% Toluene 43-48% Nitrobenzene .6-1.0% Primene 81R .5-1.0% ______________________________________Additional variations include (1) the replacement of the toluene with about 10% methanol and 90% isopropyl alcohol for toxicity reasons and (2) replacement of the toluene with 10% methanol, 45% isopropyl alcohol, and 45% kerosene as a cost-reducing factor.A preferred additive is: ______________________________________ Cupric sulfate .02% Picric acid 1.54% Methanol 35% Isopropyl alcohol 15% Toluene 48.3% Nitrobenzene .8% Primene 81R .
Abstract: The entry of animal viruses into their host cells proceeds via a specialized internalization pathway involving clathrin coated regions of the plasma membrane. In the present invention, there has been examined the effect of dansylcadaverine compared with amantadine and other antiviral agents as to the entry of vesicular stomatitis virus (VSV) into mouse cells. It was found that both compounds inhibit VSV entry. Both compounds inhibit the uptake of .alpha..sub.2 macroglobulin (.alpha.2M), a protein that binds to specific membrane receptors and follows the same route of internalization. Dansylcadaverine is 20 fold more potent than amantadine to the blocking virus and also to the .alpha..sub.2 macroglobulin uptake.
Type:
Grant
Filed:
February 26, 1982
Date of Patent:
August 2, 1983
Assignee:
The United States of America as represented by the Department of Health & Human Services
Abstract: In the detection of the highly transmittable agent of non-A, non-B hepatitis there is described a method utilizing antigen-antibody reaction and preferred counterelectrophoresis method for the detection of said antigen. This method may also be applied to producing a vaccine.
Type:
Grant
Filed:
November 10, 1981
Date of Patent:
July 26, 1983
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: A water-based paste which is curable to a flowing glass which is made generally from boric acid, silica flour, or diatomite silica. Generally, silica flour is added for pipe sealer or diatomite-type silica for cap sealers. Optional additives are latex and Kelzan for modifying rheology and trisodium phosphate to fine control the softening point. These compositions may be utilized in standpipes and collecting mains in coke ovens. The softening point of the composition is selected so that it is compatible with the operation of the coke oven. Softening temperatures for these compositions range from about 400.degree. C. to about 750.degree. C. and the boric acid and silica components were selected with a particle size ranging from about 44-210 microns.
Abstract: 6-Keto-hydroxymorphinans having at the 4 position a substituent which is R.sub.1 =H, O lower alkyl, or O lower acyl, and N may be substituted by R.sub.2, which for agonist properties may be lower alkyl, lower alkenyl, cyclopropylmethyl, or phenyl lower alkyl, etc. Additionally, the nitrogen may be substituted by R.sub.2, which is allyl, cyclopropylmethyl, cyclobutylmethyl, dimethylallyl, etc., which function as antagonists to the morphine-like activity of the compound. Such activity is known as antinociceptive.
Type:
Grant
Filed:
July 16, 1981
Date of Patent:
June 28, 1983
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Arnold Brossi, Helmut Schmidhammer, Arthur E. Jacobson
Abstract: This patent application describes the preparation and properties of novel and highly potent morphinan analgesics. The compounds include narcotic agnoists as well as narcotic antagonists and are represented by the following formula: ##STR1## R.sub.1 =OCH.sub.3, OCOCH.sub.3, H R.sub.2 =CH.sub.3, CH.sub.2 --CH.dbd.CH.sub.2, ##STR2## CH.sub.2 CH.sub.2 C.sub.6 H.sub.
Type:
Grant
Filed:
July 16, 1981
Date of Patent:
June 14, 1983
Assignee:
The United States of America as represented by Secretary of the Department of Health and Human Services
Inventors:
Arnold Brossi, Helmut Schmidhammer, Arthur E. Jacobson, Fu-Lian Hsu
Abstract: The present invention relates to a method for improving a soil structure by stabilization of aggregates. According to the invention it is applied to the soil a graft polymer substantially free of monomer, having an intrinsic viscosity below 1dg/l and a molecular weight below 100,000. The graft polymer is obtained by the exothermic reaction of a water soluble lignosulfonate with a member selected from the group consisting of acrylic acid, methacrylic acid and mixtures thereof. The graft polymers have been found to be also useful as binding reagents for agglomerating single particles of particulate materials.The graft polymers according to the invention are obtained in the form of an aqueous solution, which may be transformed into a powder by spray drying. As soil conditioners they may be applied by spraying, alone or admixed with fertilizers or pesticides and also combined with the operation of planting and soil stabilization.
Type:
Grant
Filed:
September 17, 1981
Date of Patent:
June 7, 1983
Assignee:
Technion Research & Development Foundation, Ltd.
Abstract: A process for the production of (.+-.)3-deazaaristeromycin, which is also known as (.+-.)-4-amino-1-[(1.alpha., 2.beta., 3.beta., 4.alpha.)-2,3-dihydroxy-4-(hydroxymethyl)-cyclopentyl]imidazo[4,5-c]pyridi ne, which comprises:(1) reacting 2,4-dichloro-3-nitropyridine with (.+-.)(1,4/2,3)-4-amino-2,3-dihydroxy-1-cyclopentanemethanol to give (.+-.)-(1,4/2,3)-4-(3-nitro-2-chloro-4-pyridylamino)-2,3-dihydroxy-1-cyclo pentanemethanol (compound II);(2) subsequently reducing compound II to (.+-.)-(1,4/2,3)-4(3-amino-2-chloro-4-pyridylamino)-2,3-dihydroxy-1-cyclop entanemethanol (compound III);(3) acid catalyzed cyclization of compound III to (.+-.)-4-chloro-1-(1.alpha., 2.beta., 3.beta., 4.alpha.)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl)imidazo[4,5-c]pyridin e (compound IV);(4) displacing the chloro group of compound IV to produce (.+-.)-4-hydrazino-1-(1.alpha., 2.beta., 3.beta., 4.alpha.
Abstract: Exhaust pollutants of a vehicle are reduced by providing dry, substantilly moisture-free air which is mixed with the fuel. The conventional air filter is removed and replaced by a housing containing a plurality of sealed glass tubes having inert gas therein which treats the air by subjecting it to ultraviolet rays and additional heat. The air has been initially heated to remove the moisture and subjected to an ultraviolet treatment before it reaches the housing.
Abstract: (.+-.)3-Deazaaristeromycin, also known as (.+-.)-4-amino-1-[(1.alpha., 2.beta., 3.beta., 4.alpha.)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]imidazo[4,5-c]pyridin e, utilized as a novel antiviral agent and inhibiting S-adenosylhomocysteine hydrolase in a pharmacological target in effective concentrations.
Type:
Grant
Filed:
September 16, 1981
Date of Patent:
May 31, 1983
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Peter K. Chiang, Giulio L. Cantoni, John A. Montgomery
Abstract: Alkylating agents have been found to have chemotherapeutic value in cancer treatment. The difficulty of altering the alkylation rate or specificity of alkylating agents is solved by methyl release from metallo N-methyl porphyrins in which the release rate is determined by the particular metal ion of the complex. Moreover, it has been shown that porphyrins accumulate specifically in tumors. Sodium aquo-N-methyltetra (p-sulfophenyl) porphinatocopper (II) trifluoromethanesulfonate has been shown to have activity against lymphocytic PS-P-388 (P388) leukemia in mammals. A wide range of N-substituents and metallo complexes, and their preparation are given. Anti-tumor use is demonstrated against P388 leukemia in animals.
Type:
Grant
Filed:
July 1, 1981
Date of Patent:
May 31, 1983
Assignee:
Research Foundation of the City University of New York
Abstract: A nondenaturing zwitterionic detergent for proteins which, for example, consists of an effective amount of 3-[(3-chloamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). This detergent is of extreme interest in the biological study of proteins due to its nondenaturing characteristic. Other examples of the group may be prepared from different alicyclic compounds, for example, utilizing cholic acid and in others deoxycholic acid and dehydroabietic acid. A process for the preparation of these compounds starts with cholic or the equivalent and from this is prepared the triethylammonium salt in tetrahydrofuran (THF). After the salt is completely dissolved in THF, ethyl chloroformate is added and the flask cooled to 0.degree. C. Then the mixed anhydride which forms is reacted with dimethylaminopropylamine to form the dimethylaminopropyl derivative of a carboxylic acid amide. Finally, the tertiary amine group is reacted with propanesultone to give the sulfobetaine product.
Type:
Grant
Filed:
August 19, 1981
Date of Patent:
February 8, 1983
Assignee:
The United States of America as represented by the Secretary of the Department of Health & Human Services
Abstract: A method of producing morphinan compounds which incorporates double advantages over the prior art, such as the utilization of .beta.,.gamma.-unsaturated ketones in place of the .alpha.,.beta.-unsaturated ketones previously used. Additionally, in the step where .beta.,.gamma.-unsaturated bromoketones (13 or 14) proceed to 1-bromo-N-formylnordihydrothebainone (morphinan) (17) there are utilized super acids, such as trifluoromethane sulfonic, trifluoroethane sulfonic and mixtures thereof, and also antimony pentafluoride and mixtures of hydrogen fluoride and antimony pentafluoride. Super acid works, whereas the prior art shows that cyclization in the presence of acids, even strong acids, such as sulfuric, phosphoric, do not work.